IL-17 has been implicated in the early and intermediate stages of this lymphoma, where it contributes to chronic inflammation and epidermotropism, making it a possible target for therapy [26]; the microbiota may serve as a biomarker for early detection or risk stratification of MF and SS [7, 9, 10, 12, 27]; the microbiota may be a target for novel therapeutic interventions such as probiotics, prebiotics, symbiotic, or fecal transplantation [9]; the microbiota may be a modifier for existing treatments such as chemotherapy, immunotherapy, or phototherapy [7, 9, 10, 12, 19, 27]. Here, IL17A is linked to lymphoma.